Vanguard Capital Management
CTSO icon

Vanguard Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Vanguard Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$367K Sell
94,223
-1,480
-2% -$10.2K ﹤0.01% 3723
2026
Q2 		$716K Buy
95,703
+1,704
+2% +$18K ﹤0.01% 3650
2026
Q1 		$1.06M Buy
+93,999
New +$1.28M ﹤0.01% 3535

Other funds holding CTSO

Avenir Corporation
Avenir Corporation Alexandria, Virginia $812M AUM 0.44% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return
Skylands Capital
Skylands Capital Milwaukee, Wisconsin $762M AUM 14.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $36.2B AUM 20.53% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $867M AUM 20.76% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management's CTSO Position: Q3 2026 in Review

Vanguard Capital Management reduced its Cytosorbents Corp (CTSO) stake by 1.5% in Q3 2026, selling an estimated $10.2K and leaving 94,223 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #3723.

Vanguard Capital Management first reported a position in CTSO in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.06M in Q1 2026. 25 funds tracked by Wall St. Rank hold CTSO as of Q3 2026.

  • Vanguard Capital Management held 94,223 shares of Cytosorbents Corp worth $367K as of Q3 2026.
  • Vanguard Capital Management sold 1,480 Cytosorbents Corp shares in Q3 2026, an estimated $10.2K.
  • Cytosorbents Corp made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3723 holding.
  • Vanguard Capital Management first reported a position in Cytosorbents Corp in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Cytosorbents Corp position peaked at $1.06M in Q1 2026.
  • 25 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.